GLP-1 and Hair Loss: Rates, Mechanism and Timeline

If you started shedding hair three or four months into treatment, the timing is characteristic and the most likely explanation is telogen effluvium triggered by rapid weight loss rather than a direct action of the drug on your follicles. The trial numbers are low: STEP 1 reported alopecia in roughly 3% of semaglutide 2.4 mg participants against under 1% on placebo, with similar magnitudes for tirzepatide in SURMOUNT-1. A larger cohort study has since found a significant association. Telogen effluvium is generally self-limiting once the trigger eases, which is the part most people want to know.

What the trials reported

STEP 1 recorded alopecia in about 3% of participants on semaglutide 2.4 mg compared with under 1% on placebo. SURMOUNT-1 reported similar magnitudes for tirzepatide. Those are adverse-event reports collected in trials that were not designed to study hair, so they capture what participants mentioned rather than what a dermatologist counted.

Three percent is uncommon and it is not nothing. It is also roughly triple the placebo rate, which is why the signal was taken seriously enough to look at in larger data.

The larger cohort and pharmacovigilance signal

A TriNetX cohort study published in JAAD found semaglutide and tirzepatide associated with a significantly increased risk of new-onset hair loss, covering telogen effluvium, androgenetic alopecia and alopecia areata. Cohort data of that kind establish association rather than cause, and confounding by the weight loss itself is exactly the thing it cannot separate out.

Across the reported data, telogen effluvium and androgenetic alopecia are the predominant subtypes. The signal appears dose-related, with semaglutide doses under 2 mg weekly rarely implicated and higher obesity-treatment doses more commonly associated. Females appear disproportionately affected.

Telogen effluvium and its two to four month delay

Telogen effluvium is a shift of a large fraction of follicles out of the growth phase and into the resting phase in response to a systemic stressor. Those hairs are not lost at the moment of the stressor. They are released two to four months later, when the resting phase ends, which is why the shedding arrives long after whatever caused it.

The calendar is genuinely useful here. Count back three months from when the shedding started and look at what was happening: a dose escalation, the steepest part of your weight loss, an illness, or a period when you were eating very little. The lag is also why shedding so often begins when someone feels they are doing well, which makes the drug feel like the obvious culprit.

Rate of weight loss as the driver

The mechanism proposed across the literature is not follicular. Rate and magnitude of weight loss is the leading proposed driver behind several of this class's cosmetic effects, hair shedding among them, alongside facial volume loss and gallstone formation.

Rapid loss, low energy availability and shortfalls in protein or micronutrients are classic telogen effluvium triggers in any context, including after bariatric surgery and in crash dieting. What is new is that a drug now produces loss at that magnitude routinely. Because rate of loss is the lever, slowing titration is what gets discussed, and that decision sits with a prescriber rather than with you.

Protein and micronutrient intake

Hair is protein, and it is metabolically expendable when supply is short. Total food volume falls sharply on this class, and protein is the most satiating macronutrient, so it is often the first thing left unfinished.

Protein intakes of about 1.2 to 1.6 g/kg/day during energy restriction preserve lean mass better than the 0.8 g/kg/day RDA, and that evidence comes from general weight-loss research rather than GLP-1 trials. Iron in particular is worth naming: iron deficiency is an established cause of diffuse shedding on its own, and intake falls with portion size. Whether to test for it is a clinician's call.

Does it regrow?

Telogen effluvium is generally self-limiting. Once the trigger eases, the follicles cycle back into growth, and density recovers over months rather than weeks. That is the usual course, and it is why dermatologists tend to advise patience over intervention for diffuse shedding with a clear trigger.

Two caveats. Shedding that continues past about six months is no longer behaving like a simple effluvium and warrants assessment. Androgenetic alopecia also appeared in the cohort data, and that is a different condition with a different course: a systemic stressor can unmask or accelerate pattern loss that was going to happen anyway, and that part does not simply reverse.

The evidence, one row per claim

Questions people ask

Sources

1. GLP-1 therapies and hair loss: a systematic review (PMC)
2. Risk of new-onset hair loss with semaglutide and tirzepatide, JAAD

Keep reading

• GLP-1 and Protein: How Much, and Why It Is Hard to EatThe protein evidence predates GLP-1s and is solid. The new problem is not the target, it is reaching one when
• "Ozempic Face": Facial Volume Loss on a GLP-1A weight-loss phenomenon with a drug's name attached. The useful content is why facial fat behaves differently
• GLP-1 and Working Out: Strength Training, Muscle Loss and ProteinLean mass loss is real and measured. The trials that measured it mostly had nobody lifting, so treat those num
• GLP-1 and Energy: Fatigue, Gym Performance and What Causes ItFatigue on a GLP-1 usually has a findable cause. Separate the fixable from the expected instead of accepting i